Cytosorbents Corporation
CTSO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $50 | $50 | $68 | $182 |
| - Cash | $3 | $14 | $22 | $52 |
| + Debt | $27 | $18 | $18 | $14 |
| Enterprise Value | $73 | $54 | $64 | $143 |
| Revenue | $36 | $31 | $35 | $40 |
| % Growth | 14.5% | -10.4% | -13.5% | – |
| Gross Profit | $25 | $22 | $21 | $29 |
| % Margin | 70.6% | 70.6% | 59.8% | 72.5% |
| EBITDA | -$15 | -$28 | -$30 | -$22 |
| % Margin | -42.7% | -89.7% | -86.5% | -53.9% |
| Net Income | -$21 | -$29 | -$33 | -$25 |
| % Margin | -58.2% | -94.1% | -94.6% | -61.2% |
| EPS Diluted | -0.38 | -0.65 | -0.75 | -0.57 |
| % Growth | 41.5% | 13.3% | -31.6% | – |
| Operating Cash Flow | -$14 | -$22 | -$28 | -$14 |
| Capital Expenditures | -$0 | -$1 | -$6 | -$4 |
| Free Cash Flow | -$15 | -$23 | -$35 | -$18 |